Obinutuzumab

BNF:

8.2.3

Status:

Red

Decision Date:

July 2015

Comments

RED^1,2,3: NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia.

RED^1,2,3: NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab. (Decision date  - September 2017)

RED^1,2,3: NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma. (Decision date  - April 2018)

RED^1,2,3: NICE TA629: Obinutuzumab with bendamustine followed by obinutuzumab maintenance for treating follicular lymphoma that did not respond or progressed up to 6 months after treatment with rituximab  (Decision date - June 2020)

RED: SSC2579: Obinutuzumab elective therapy to prevent immune Thrombotic Thrombocytopenic Purpura (TTP) relapse in patients who are refractory or intolerant to rituximab (adults) as per NHSE commissioning intentions (Decision - December 2023)

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again